Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/art.20617 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Golimumab-Induced Anti-NuMA-1 (Nuclear Mitotic Apparatus Protein 1) Antibodies in a Rheumatoid Arthritis Patient: A Case Report.
Cureus
November 2024
Department of Rheumatology B, Ayachi Hospital, Ibn Sina Hospital Center, Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, MAR.
Anti-nuclear mitotic apparatus (NuMA) 1 antibodies are uncommonly detected in routine antinuclear antibody (ANA) screening. We present the case of a 65-year-old female with rheumatoid arthritis undergoing golimumab biotherapy who developed lupus-like symptoms including photosensitivity, fatigue, weakness, myalgias, alopecia, oral ulcers, and worsening of arthritis. Elevated serum levels of NuMA-1 antibodies were detected using indirect immunofluorescence (IIF) on HEp-2 cells with a titer of 1:1000, but no other ANA patterns were associated.
View Article and Find Full Text PDFExposure to Gold Induces Autoantibodies against Nuclear Antigens in A.TL Mice.
Biology (Basel)
October 2024
Division of Clinical Chemistry and Pharmacology (KKF), Department of Biomedical and Clinical Sciences (BKV), Linköping University, 581 83 Linköping, Sweden.
To demonstrate causation or/and assess pathogenic mechanisms of environment-induced autoimmunity, various animal models that mimic the characteristics of the human autoimmune diseases need to be developed. Experimental studies in mice reveal the genetic factors that contribute to autoimmune diseases. Here, the immune response of two mouse strains congenic for non-H-2 genes, A.
View Article and Find Full Text PDFLong-term outcome of tacrolimus-based immunosuppressive treatment for patients with paediatric-onset lupus nephritis.
Nephrology (Carlton)
December 2024
Department of Nursing, Faculty of Health and Medical Care, Hachinohe Gakuin University, Hachinohe, Japan.
Aim: We have previously reported the mid-term efficacy and safety of tacrolimus (Tac)-based immunosuppressive therapy in such patients, and herein, we aimed to determine their long-term outcomes (over 10 years).
Methods: We retrospectively evaluate the data of 13 consecutive patients with biopsy-proven long-standing LN who underwent a long-term Tac-based treatment regimen. Tac was administered once daily at a dose of 3 mg as reinduction or maintenance treatment.
Progranulin mediates the onset of pristane induced systemic lupus erythematosus.
Adv Rheumatol
September 2024
Department of Orthopaedic Surgery, New York University Medical Center, New York, NY, 10003, USA.
Backgrounds: Progranulin (PGRN) is a growth factor-like molecule with diverse roles in homeostatic and pathogenic processes including the control of immune and inflammatory responses. Pathogenic inflammation is a hallmark of systemic lupus erythematosus (SLE) and elevated serum levels of PGRN has been evaluated as a biomarker of disease activity in SLE. However, the role of PGRN in SLE has not been fully investigated.
View Article and Find Full Text PDFCathepsin B Nuclear Flux in a DNA-Guided "Antinuclear Missile" Cancer Therapy.
ACS Cent Sci
August 2024
Department of Therapeutic Radiology, Yale School of Medicine, New Haven, Connecticut 06510, United States.
Some antinuclear antibodies (ANAs) bind extracellular nucleic acids released into tumor environments and are pulled into the nuclei of live cancer cells through nucleoside salvage pathways, independent of tumor-specific surface antigens. Here we show that ANA nuclear penetration induces nuclear flux by the lysosomal protease cathepsin B and leverage this mechanism to design an antinuclear antibody-drug conjugate (ANADC) with cathepsin B-labile drug linker. The ANADC targets nucleic acid exhaust from necrotic tumors and crosses membrane barriers through nucleoside salvage as a DNA-seeking and tumor agnostic "antinuclear missile" cancer therapy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!